Literature DB >> 29730782

Myeloma light chain cast nephropathy, a review.

Insara Jaffer Sathick1, Maria Eleni Drosou2, Nelson Leung3,4.   

Abstract

Multiple Myeloma is a plasma cell proliferative disorder that commonly involves the kidney. Renal impairment is a serious complication during the course of the disease that is associated with increased morbidity and mortality. Light chain cast nephropathy is the predominant pattern of renal injury in Multiple Myeloma. This review article focuses on the pathophysiology and diagnostic approach of myeloma cast nephropathy. The management of precipitating factors as well as anti-plasma cell treatment modalities in the context of renal impairment are also discussed.

Entities:  

Keywords:  Light chain cast nephropathy; Multiple myeloma

Mesh:

Substances:

Year:  2018        PMID: 29730782     DOI: 10.1007/s40620-018-0492-4

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  121 in total

1.  Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma.

Authors:  K Oshima; Y Kanda; Y Nannya; M Kaneko; T Hamaki; M Suguro; R Yamamoto; A Chizuka; T Matsuyama; N Takezako; A Miwa; A Togawa; H Niino; M Nasu; K Saito; T Morita
Journal:  Am J Hematol       Date:  2001-05       Impact factor: 10.047

2.  Renal involvement in multiple myeloma: a 10-year study.

Authors:  V Sakhuja; V Jha; S Varma; K Joshi; K L Gupta; K Sud; H S Kohli
Journal:  Ren Fail       Date:  2000       Impact factor: 2.606

3.  Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Authors:  M Drayson; L X Tang; R Drew; G P Mead; H Carr-Smith; A R Bradwell
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

4.  Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

Authors:  Glen S Markowitz; Gerald B Appel; Paul L Fine; Andrew Z Fenves; Nicholas R Loon; Sundar Jagannath; Joseph A Kuhn; Adam D Dratch; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2001-06       Impact factor: 10.121

5.  Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series.

Authors:  L Moist; G Nesrallah; C Kortas; E Espirtu; T Ostbye; W F Clark
Journal:  Am J Nephrol       Date:  1999       Impact factor: 3.754

6.  Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.

Authors:  L M Knudsen; M Hjorth; E Hippe
Journal:  Eur J Haematol       Date:  2000-09       Impact factor: 2.997

7.  Managing the complications of plasma cell myeloma.

Authors:  H J Cohen; R W Rundles
Journal:  Arch Intern Med       Date:  1975-01

8.  Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein.

Authors:  W Z Ying; P W Sanders
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

9.  Multiple myeloma: review of 869 cases.

Authors:  R A Kyle
Journal:  Mayo Clin Proc       Date:  1975-01       Impact factor: 7.616

10.  Cast nephropathy in a case of Waldenström's macroglobulinemia.

Authors:  Jorge Isaac; Guillermo A Herrera
Journal:  Nephron       Date:  2002-07       Impact factor: 2.847

View more
  8 in total

Review 1.  Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.

Authors:  Paolo Menè; Antonella Stoppacciaro; Silvia Lai; Francescaromana Festuccia
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-05-13

Review 2.  Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms.

Authors:  Mengsi Hu; Qianhui Wang; Bing Liu; Qiqi Ma; Tingwei Zhang; Tongtong Huang; Zhimei Lv; Rong Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-18

3.  [IgD multiple myeloma mimicking free light chain myeloma complicated by factor X deficiency: a case report].

Authors:  Najat Lasri; Fatimazahra Lahlimi; Mohammed Ilias Tazi; Sophie Rigaudeau
Journal:  Pan Afr Med J       Date:  2022-04-27

Review 4.  Two kinds of rare light chain cast nephropathy caused by multiple myeloma: case reports and literature review.

Authors:  Li-Jun Sun; Hong-Rui Dong; Xiao-Yi Xu; Guo-Qin Wang; Hong Cheng; Yi-Pu Chen
Journal:  BMC Nephrol       Date:  2021-01-28       Impact factor: 2.388

5.  Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.

Authors:  Jinzhou Wang; Xiangjun Shi; Xingchen Yao; Jie Ren; Xinru Du
Journal:  J Healthc Eng       Date:  2021-09-13       Impact factor: 2.682

6.  Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy-Analysis of 130 Eyes of 65 Subjects.

Authors:  Kitti Kormányos; Klaudia Kovács; Orsolya Németh; Gábor Tóth; Gábor László Sándor; Anita Csorba; Cecília Nóra Czakó; László Módis; Achim Langenbucher; Zoltán Zsolt Nagy; Gergely Varga; László Gopcsa; Gábor Mikala; Nóra Szentmáry
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

7.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

8.  Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects.

Authors:  Kitti Kormányos; Klaudia Kovács; Orsolya Németh; Gábor Tóth; Gábor László Sándor; Anita Csorba; Cecília Nóra Czakó; Achim Langenbucher; Zoltán Zsolt Nagy; Gergely Varga; László Gopcsa; Gábor Mikala; Nóra Szentmáry
Journal:  J Ophthalmol       Date:  2021-06-18       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.